Ironwood Pharmaceuticals Inc. Cl A | Ownership
Companies that own Ironwood Pharmaceuticals Inc. Cl A
Wellington Management Co. LLP
19,263,267
13.84%
131,437
0.07%
06/30/2018
Fidelity Management & Research Co.
17,995,391
12.93%
544,028
0.04%
06/30/2018
The Vanguard Group, Inc.
11,656,328
8.38%
442,362
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
11,168,591
8.02%
-1,041,860
0.03%
06/30/2018
BlackRock Fund Advisors
10,663,102
7.66%
522,501
0.01%
06/30/2018
Henderson Global Investors Ltd.
8,067,938
5.8%
-59,350
0.07%
06/30/2018
Brown Capital Management LLC
6,305,456
4.53%
40,631
1.07%
06/30/2018
Ecor1 Capital LLC
6,250,073
4.49%
364,490
12.5%
06/30/2018
SSgA Funds Management, Inc.
5,537,623
3.98%
-495,447
0.01%
06/30/2018
Sarissa Capital Management LP
3,367,100
2.42%
0
11.46%
06/30/2018
| Address |
301 Binney Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.ironwoodpharma.com |
| Updated |
07/08/2019 |
| Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. |
